Cue Biopharma is trading 9.98% up now at $36.13 as investors continue reacting to positive September 20 topline Phase 2 results for CUE-221. - The study met its primary and key secondary endpoints with high statistical significance, while safety remained favorable. - The company is advancing toward a Phase 2b/3 study, supporting continued momentum after recent volatility. - Broader markets are modestly higher, but the company-specific clinical update appears to be the stronger catalyst.